Product Details:
| Form | Injection |
| Packaging Size | Vial |
| Purity | 99% |
| Brand | Peptide Sceince |
| Packaging Type | Box |
Product Details:
| Form | Injection |
| Packaging Type | Vial |
| Packaging Size | 10 Vials |
| Purity | 99% |
| Brand | Peptide Science |
Product Details:
| Form | Injection |
| Packaging Type | Box |
| Packaging Size | Vial |
| Purity | 99% |
| Brand | Peptide Science |
Retatrutide is a triple hormone (GIP, GLP-1 and glucagon) receptor agonist in development for the treatment of obesity.
Obesity is a complex disease that occurs when an individual's weight is higher than what is considered healthy for his/her height. According to the CDC, people with a body mass index (BMI) between 25 and 29.9 are considered overweight, and people with a BMI of 30 or higher are considered obese.
Retatrutide works in the treatment of obesity by targeting three different hunger regulating hormones:
- GIP (gastric inhibitory peptide or glucose-dependent insulinotropic polypeptide) is an incretin hormone that is released from the gut after eating. It stimulates the beta-cells in the pancreas to secrete insulin.
- GLP-1 (glucagon-like peptide-1) is also an incretin hormone that stimulates the beta-cells to secrete insulin.